Managing Director Paul Guilfoyle owns ~6% of company shares, purchasing additional shares from non-executive director Marcus Machin in July 2021 at ~$.03 per share.

$6.7m cash in bank, enough to sustain the business for 2 QTRs. Of note, at EOFY 2020 the company had $11.3m cash in bank which was enough to sustain 88 QTRs, indicating a marked increase in spend over FY2021.

Capital raise in 4th QTR 2021 of $7.6m via a private Placement at an issue price of $.032 per share, with 23,842,185 shares issued. Two additional capital raises occurred in 2020, totalling $10m.

Claimed increase spending 4Q21 on personnel, admin and "corporate costs" (~$1.45m) were to "reflect growth in operations consistent with Phase 1 of 3 phase strategic plan". The balance sheet however when compared to EOFY 2020 did not show a material difference in staff costs or admin (increase of ~.05m). R&D did increase from $0 to ~$1.5m however product manufacturing and operating costs reduced from ~$7.3m to ~4.8m.

As of 9th July 2021, 522,056,844 shares on issue with 72,520,000 options/conv notes/performance rights quoted.

EOFY 2021 the reported revenue was $3.875m (with $5.8m claimed revenue owing or yet to be invoiced). Revenue at EOFY 2020 was $11.785m. Of note, revenues up to and including 2019 were essentially non-existant.